- MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
- MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder
Key statistics
On Friday, Numinus Wellness Inc (NUMIF:QXE) closed at 0.0518, 3.60% above its 52-week low of 0.05, set on Apr 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0525 |
---|---|
High | 0.053 |
Low | 0.0513 |
Bid | -- |
Offer | -- |
Previous close | 0.0522 |
Average volume | 125.08k |
---|---|
Shares outstanding | 316.46m |
Free float | 304.12m |
P/E (TTM) | -- |
Market cap | 22.15m CAD |
EPS (TTM) | -0.1022 CAD |
Data delayed at least 15 minutes, as of May 03 2024 19:53 BST.
More ▼